Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Alexandre Sepriano
  • Sofia Ramiro
  • Oliver FitzGerald
  • Mikkel Østergaard
  • Joanne Homik
  • Désirée van der Heijde
  • Ori Elkayam
  • Carter Thorne
  • Maggie J Larché
  • Gianfranco Ferraccioli
  • Marina Backhaus
  • Gerd R Burmester
  • Gilles Boire
  • Bernard Combe
  • Alain Saraux
  • Maxime Dougados
  • Maurizio Rossini
  • Marcello Govoni
  • Luigi Sinigaglia
  • Alain Cantagrel
  • Cheryl Barnabe
  • Clifton O Bingham
  • Paul P Tak
  • Dirkjan van Schaardenburg
  • Hilde Berner Hammer
  • Joel Paschke
  • Rana Dadashova
  • Edna Hutchings
  • Robert Landewé
  • Walter P Maksymowych
View graph of relations

OBJECTIVE: Compelling evidence supports a treat-to-target (T2T) strategy for optimal outcomes in rheumatoid arthritis (RA). There is limited knowledge regarding the factors that impede implementation of T2T, particularly in a setting where adherence to T2T is protocol-specified. We aimed to assess clinical factors that associate with failure to adhere to T2T.

METHODS: Patients with RA from 10 countries who were starting or changing conventional synthetic disease-modifying antirheumatic drugs and/or starting tumor necrosis factor inhibitors were followed for 2 years. Participating physicians were required per protocol to adhere to the T2T strategy. Factors influencing adherence to T2T low disease activity (T2T-LDA; 44-joint count Disease Activity Score ≤ 2.4) were analyzed in 2 types of binomial generalized estimating equations models: (1) including only baseline features (baseline model); and (2) modeling variables that inherently vary over time as such (longitudinal model).

RESULTS: A total of 571 patients were recruited and 439 (76.9%) completed 2-year followup. Failure of adherence to T2T-LDA was noted in 1765 visits (40.5%). In the baseline multivariable model, a high number of comorbidities (OR 1.10, 95% CI 1.02-1.19), smoking (OR 1.32, 95% CI 1.08-1.63) and high number of tender joints (OR 1.03, 95% CI 1.02-1.04) were independently associated with failure to implement T2T, while anticitrullinated protein antibody/rheumatoid factor positivity (OR 0.63, 95% CI 0.50-0.80) was a significant facilitator of T2T. Results were similar in the longitudinal model.

CONCLUSION: Lack of adherence to T2T in the RA BIODAM cohort was evident in a substantial proportion despite being a protocol requirement, and this could be predicted by clinical features. [Rheumatoid Arthritis (RA) BIODAM cohort; ClinicalTrials.gov: NCT01476956].

Original languageEnglish
JournalJournal of Rheumatology
ISSN0315-162X
DOIs
Publication statusE-pub ahead of print - 2020

ID: 58908459